Maaly Abdel Halim Abdel Fattah1,2,3*, Tariq Abdulmohsen Al-Anazi2, Sara Sohail Kayali3, Yasser Saleh Almuzaini4 and Faisal Mesfer AlQahtani2
1Ophthalmology Department, Cairo University, College of Medicine, Cairo, Egypt
2Ophthalmology Department, King Faisal Specialist Hospital and Research Center, Riyadh, Saudi Arabia
3Al-Faisal University College of Medicine, Riyadh, Saudi Arabia
4Imam Abdulrahman Bin Faisal University, College of Medicine, Riyadh, Saudi Arabia
*Corresponding Author: Maaly Abdel Halim Abdel Fattah, Ophthalmology Department, King Faisal Specialist Hospital and Research Center, Riyadh, Saudi Arabia.
Received: May 15, 2021; Published: May 22, 2021
Oral anti vascular endothelial growth factors therapeutic agents have been evolving rapidly over the last past decades and became one of the great contributors to advancement of cancer therapy and increasing survival rate of the treated patients.
Sorafenib is FDA approved medications for the treatment of solid tumors.
In this article, we reported the clinical features of the first Saudi patient presenting with corneo-uveal retinal adverse effects with subsequent bilateral irreversible blindness.
Keywords: Hepatocellular Carcinoma; Targeted Anti-Cancer Therapy; Sorafenib; Oral Anti-Vascular Endothelial Growth Factor; Ocular Toxicity; Irreversible Blindness
Citation: Maaly Abdel Halim Abdel Fattah., et al. “Corneo-Uveal-Retinal Adverse Effects after Single Course of Targeted Anti-Cancer Therapy: Case Report and Review of Literature".Acta Scientific Ophthalmology 4.6 (2021): 69-75.
Copyright: © 2021 Maaly Abdel Halim Abdel Fattah., et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.